​

Citius Pharmaceuticals (CTXR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CTXR Stock Rating

Citius Pharmaceuticals stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (83.33%), 1 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 1 5 0 Strong Sell Sell Hold Buy Strong Buy

CTXR Price Target Upside V Benchmarks

TypeNameUpside
StockCitius Pharmaceuticals-
SectorHealthcare Stocks 18.80%
IndustryBiotech Stocks 54.28%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.54$1.54$1.54
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 25-11--2
Jun, 25-11--2
May, 2521---3
Apr, 2521---3
Mar, 2521---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 23, 2025CitigroupBuyHolddowngrade
Dec 30, 2024CitigroupBuyupgrade
Aug 19, 2024EF HuttonBuyBuyhold
Jul 15, 2024EF HuttonBuyinitialise

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-0.23$-0.23------
Avg Forecast$-0.22$-4.00$-5.72$-1.84$1.36$2.50$3.60$4.44
High Forecast$-0.16$-4.00$-4.44$-1.43$1.91$3.44$5.07$6.27
Low Forecast$-0.26$-4.00$-8.07$-2.60$1.05$1.55$2.79$3.45
Surprise %4.55%-94.25%------

Revenue Forecast

$0 $120M $240M $360M $480M $600M Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported--------
Avg Forecast$103.16M-$61.72M$39.59M$125.20M$231.29M$344.98M$423.08M
High Forecast$120.48M-$81.26M$52.12M$164.84M$304.50M$454.18M$557.01M
Low Forecast$83.03M-$51.14M$32.80M$103.73M$191.62M$285.81M$350.51M
Surprise %--------

Net Income Forecast

$-2B $-900M $-300M $300M $900M $2B Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-33.64M$-32.54M$-39.43M-----
Avg Forecast$-32.53M$-605.18M$-1.09B$-350.05M$258.10M$433.77M$625.02M$771.92M
High Forecast$-24.28M$-605.18M$-772.73M$-248.57M$332.93M$598.07M$882.22M$1.09B
Low Forecast$-39.63M$-605.18M$-1.40B$-451.54M$183.27M$269.48M$485.66M$599.81M
Surprise %3.42%-94.62%-96.38%-----

CTXR Forecast FAQ

Is Citius Pharmaceuticals stock a buy?

Citius Pharmaceuticals stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Citius Pharmaceuticals is a favorable investment for most analysts.

What is Citius Pharmaceuticals's price target?

Citius Pharmaceuticals's price target, set by 6 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.54.

How does Citius Pharmaceuticals stock forecast compare to its benchmarks?

Citius Pharmaceuticals's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (18.80%) and underperforming the biotech stocks industry (54.28%).

What is the breakdown of analyst ratings for Citius Pharmaceuticals over the past three months?

  • July 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Citius Pharmaceuticals’s EPS forecast?

Citius Pharmaceuticals's average annual EPS forecast for its fiscal year ending in September 2025 is $-1.84, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $1.36 in 2026, $2.5 in 2027, $3.6 in 2028, and $4.44 in 2029.

What is Citius Pharmaceuticals’s revenue forecast?

Citius Pharmaceuticals's average annual revenue forecast for its fiscal year ending in September 2025 is $39.59M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $125.2M, followed by $231.29M for 2027, $344.98M for 2028, and $423.08M for 2029.

What is Citius Pharmaceuticals’s net income forecast?

Citius Pharmaceuticals's net income forecast for the fiscal year ending in September 2025 stands at $-350M, representing an 787.88% increase from the reported $-39.426M in 2024. Projections indicate $258.1M in 2026, $433.77M in 2027, $625.02M in 2028, and $771.92M in 2029.